Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duo Dong

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Scientific Reports|May 1, 2023
N,N-dimethylacetamide targets neuroinflammation in Alzheimer's disease in in-vitro and ex-vivo modelsZeng-Hui Wei, Jagadish Koya, Nikita Acharekar, et al.
Bioorganic Chemistry|March 26, 2023
Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitorsGao-Jie Ye, Chao-Yun Cai, Xing-Duo Dong, et al.
American Journal of Cancer Research|January 8, 2024
Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterizationMeng Zhang, Min-Na Huang, Xing-Duo Dong, et al.
Frontiers in Oncology|August 15, 2020
NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug ResistanceMeng Zhang, Xuan-Yu Chen, Xing-Duo Dong, et al.
Frontiers in Oncology|July 17, 2020
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer CellsWeiguo Feng, Meng Zhang, Zhuo-Xun Wu, et al.
Frontiers in Cell and Developmental Biology|September 28, 2020
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer CellsXing-Duo Dong, Meng Zhang, Xiubin Ma, et al.
Frontiers in Pharmacology|March 14, 2022
Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer CellsXing-Duo Dong, Meng Zhang, Chao-Yun Cai, et al.
Frontiers in Oncology|July 18, 2020
Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer CellsYi-Dong Li, Yong Mao, Xing-Duo Dong, et al.
Journal of Translational Internal Medicine|July 31, 2024
RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cellsXing-Duo Dong, Qisi Lu, Yi-Dong Li, et al.
Cancer Letters|October 31, 2024
Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studiesXing-Duo Dong, Meng Zhang, Qiu-Xu Teng, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Scientific Reports|May 1, 2023
N,N-dimethylacetamide targets neuroinflammation in Alzheimer's disease in in-vitro and ex-vivo modelsZeng-Hui Wei, Jagadish Koya, Nikita Acharekar, et al.
Bioorganic Chemistry|March 26, 2023
Design, synthesis, and biological evaluation of phenylurea indole derivatives as ABCG2 inhibitorsGao-Jie Ye, Chao-Yun Cai, Xing-Duo Dong, et al.
American Journal of Cancer Research|January 8, 2024
Overexpression of ABCB1 confers resistance to FLT3 inhibitor FN-1501 in cancer cells: in vitro and in vivo characterizationMeng Zhang, Min-Na Huang, Xing-Duo Dong, et al.
Frontiers in Oncology|August 15, 2020
NVP-CGM097, an HDM2 Inhibitor, Antagonizes ATP-Binding Cassette Subfamily B Member 1-Mediated Drug ResistanceMeng Zhang, Xuan-Yu Chen, Xing-Duo Dong, et al.
Frontiers in Oncology|July 17, 2020
Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer CellsWeiguo Feng, Meng Zhang, Zhuo-Xun Wu, et al.
Frontiers in Cell and Developmental Biology|September 28, 2020
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer CellsXing-Duo Dong, Meng Zhang, Xiubin Ma, et al.
Frontiers in Pharmacology|March 14, 2022
Overexpression of ABCB1 Associated With the Resistance to the KRAS-G12C Specific Inhibitor ARS-1620 in Cancer CellsXing-Duo Dong, Meng Zhang, Chao-Yun Cai, et al.
Frontiers in Oncology|July 18, 2020
Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer CellsYi-Dong Li, Yong Mao, Xing-Duo Dong, et al.
Journal of Translational Internal Medicine|July 31, 2024
RN486, a Bruton's Tyrosine Kinase inhibitor, antagonizes multidrug resistance in ABCG2-overexpressing cancer cellsXing-Duo Dong, Qisi Lu, Yi-Dong Li, et al.
Cancer Letters|October 31, 2024
Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studiesXing-Duo Dong, Meng Zhang, Qiu-Xu Teng, et al.
Pageof 4